Thursday, 01 October 2020


Huahai gets China FDA nod to make HIV/AIDS generic

25 September 2013 | Regulatory | By BioSpectrum Bureau

Good news for HIV / AIDS patients - Zhejiang Huahai gets nod from China FDA to produce efavirenz

Good news for HIV / AIDS patients - Zhejiang Huahai gets nod from China FDA to produce efavirenz

Singapore: China-based Zhejiang Huahai Pharma received approval from the China FDA to produce efavirenz. Huahai is the first Chinese drugmaker to receive approval to make the drug.

The drug is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI), which can be used to control the symptoms of AIDS.

Huahai was earlier involved in the production of efavirenz active pharmaceutical ingredient (API) for Merck, which marketed the drug under the name Stocrin.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account